<DOC>
	<DOCNO>NCT00603434</DOCNO>
	<brief_summary>This human inpatient clinical pharmacology study assess potential interaction intravenous ( i.v . ) methamphetamine infusion oral osmotic release methylphenidate ( OROS-MPH ) . The primary objective study determine safety OROS-MPH concurrent i.v . d-methamphetamine infusion 15 mg 30 mg. Safety outcome measure include cardiovascular response [ heart rate ( HR ) , blood pressure ( BP ) , electrocardiograph ( ECG ) measurement ] , oral temperature , adverse event ( AEs ) , clinical laboratory analysis .</brief_summary>
	<brief_title>Safety Assessment Potential Interactions Between IV Methamphetamine Osmotic-Release Methylphenidate ( OROS-MPH )</brief_title>
	<detailed_description />
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Be volunteer meet DSMIV criterion methamphetamine abuse dependence determine use MiniInternational Neuropsychiatric Interview ( MINI ) nontreatment seek time study positive urine test methamphetamine ( great = 500 ng/mL ) screening . Be able verbalize understanding consent form , able provide write informed consent , verbalize willingness complete study procedure . Have negative urine test methamphetamine drug abuse ( opiate , cocaine , benzodiazepine ) clinic intake first infusion session . Have history physical examination demonstrate clinically significant contraindication participate study , judgment admit physician site Principal Investigator Have vital sign follow : resting heart rate 45 100 bpm , systolic BP 140 mm Hg diastolic BP 90 mm Hg . Have electrolyte ( Na , K , Cl , HCO3 ) hematocrit clinically normal ( +/ 10 % laboratory limit ) . Have liver function test ( total bilirubin , ALT , AST , alkaline phosphatase ) less three time upper limit normal . Have kidney function test ( creatinine BUN ) less twice upper limit normal . Have ECG perform demonstrate sinus rhythm 45 100 beat per minute ( bpm ) , normal conduction , clinically significant arrhythmia . Be able swallow whole tablet OROSMPH due control release formulation . If female , negative pregnancy test agree use one follow method birth control , postmenopausal , hysterectomy sterilize . Birth control must effect start least 7 day ( 14 day hormonebased method use alone ) prior clinic intake , extend least last followup visit . Please contact site information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Methamphetamine</keyword>
</DOC>